On June 19, 2025, the highly anticipated "2024 Yangtze River Delta G60 Science and Technology Innovation Corridor U30 Youth Entrepreneurship List and 'Starlight G60' Entrepreneurship Talent List" award ceremony was successfully held at the G60 Science and Technology Innovation Building in Lingang Songjiang Science and Technology City. This grand event, which brought together the innovative and entrepreneurial elites from the Yangtze River Delta region, was guided by the China Association for Science and Technology and jointly hosted by the Science and Technology Communication Center of the China Association for Science and Technology, the Shanghai Association for Science and Technology, and the People's Government of Songjiang District, Shanghai. It attracted many young entrepreneurs with dreams and the courage to innovate.

In this intense selection process, Dr. Xie Tianfa, a partner and R&D director of Yuanwu Medical, stood out among many outstanding candidates with his remarkable innovative capabilities and excellent entrepreneurial achievements, and was successfully included in the "2024 Yangtze River Delta G60 Science and Technology Innovation Corridor U30 Youth Entrepreneurship List".

This list has attracted the enthusiastic participation of many science and technology innovation enterprises. Dr. Xie Tianfa's successful listing this time is not only a high recognition of his personal innovation and entrepreneurship capabilities in the field of cutting-edge technology, but also a full affirmation of the breakthrough progress he has led his team to make in the field of cell therapy technology. This fully demonstrates his outstanding achievements as a representative of young scientific and technological innovators and entrepreneurs on the path of pioneering and innovation, as well as his positive contributions to promoting the integration and innovative development of industry, academia, research and medicine in the country's "high-precision and cutting-edge" industries.

Dr. Xie Tianfa is a partner and the head of R&D at Yuanwu Medical

Doctor of Engineering from the University of Massachusetts Amherst, USA, with over six years of overseas study and research experience in the field of stem cells, and has accumulated rich project practice and management experience. During my doctoral studies, I conducted in-depth research on the regulation of the in vitro directed induction and differentiation of pluripotent stem cells through biomechanics. I successfully constructed models of ectodermal development and early midbrain and posterior brain spatial development using human pluripotent stem cells (hESC, hiPSC). After graduation, I joined ScienCell, a biotech company located in California, USA, as a research and development scientist, leading the in vitro directed induction and differentiation of neural stem cells and cardiomyocytes as well as the development of stem cell culture media. After achieving remarkable success overseas, with his sincere love for his motherland and passion for the medical profession, he resolutely gave up the favorable research conditions and living benefits abroad and chose to return to China to devote himself to the cutting-edge field of domestic medical science and technology. He joined the Yuanwu Medical startup team and was fully responsible for the research and development of ready-to-use cell drugs for Parkinson's disease (PD) based on biomechanics. By regulating the mechanical signal transduction pathways of cells, he improved the induction and differentiation efficiency of midbrain dopaminergic neural precursor cells, allowing for transplantation without sorting, reducing production costs and enhancing the accessibility of PD cell drugs. In addition, a total of 11 papers have been published in multiple high-level academic journals: among them, 2 are first-author SCI research papers (the ectoderm development model results were published in Matter (under Cell Press), with an impact factor of 19.97; The biomechanical research paper was published in eLife with an impact factor of 8.71. Two core technology invention patents related to the induction and differentiation of midbrain dopaminergic neural precursor cells have been authorized, among which one has applied for PCT, demonstrating the international competitiveness and forward-looking nature of its technology. He is also a member of the International Society for Stem Cell Research (ISSCR) and the American Society for Biomedical Engineering (BMES), and serves as a reviewer for several academic journals.

Strengthen technology and empower through innovation. Dr. Xie Tianfa has always remained true to his original aspiration, brimming with boundless passion for science and technology and a firm belief in innovation. He has continuously delved into the field of cell therapy, combining his academic strengths and practical experience. With his outstanding leadership skills, profound professional expertise, and unwavering spirit of innovation, he has led his team to steadily advance in the fierce competition. In the future, Yuanwu Medical will continue to focus on the core technology field of cell therapy, constantly explore and break through innovations, and be committed to accelerating the pace of innovative products moving from the laboratory to clinical practice, providing more efficient and advanced treatment solutions for the cause of human health. Meanwhile, Yuanwu Medical also looks forward to working hand in hand with more like-minded partners and entrepreneurial pioneers to continuously inject powerful impetus into regional innovative development, drive the technological engine to accelerate its pace, forge ahead towards higher goals, and open a brand-new chapter in the development of medical science and technology.

Regarding the U30 Youth Entrepreneurship List of the G60 Science and Technology Innovation Corridor in the Yangtze River Delta

The "U30 List" is an important event initiated by the Science and Technology Communication Center of the China Association for Science and Technology. Centering on national science and technology innovation center cities and innovation hub cities, it focuses on the Yangtze River Delta region and selects 30 young entrepreneurs under the age of 35 every year. This event aims to discover and cultivate young innovative and entrepreneurial talents, build a platform for communication and connection between young people and the government, society and investment institutions, and promote the high-quality development of future industries. Since its establishment in 2021, the list has not only effectively gathered intellectual resources from all sides, explored new driving forces for the integration of technology, finance and culture, but also created a new platform and provided a new stage for the growth of young innovative and entrepreneurial talents, and offered strong support to technology entrepreneurs.

Regarding Yuanwu Medicine

Shanghai Yuanwu Medical Technology Co., Ltd. is a regenerative medicine company dedicated to the development and application of iPSC (Induced pluripotent stem Cells) technology. Founded in 2021, it has been certified as a national-level technology-based small and medium-sized enterprise. In the three key areas of cell reprogramming, directed differentiation, and cell engineering, it has applied for 37 globally leading independent intellectual property rights, including 12 invention patents. Among them, six have been authorized and two have applied for PCT, providing solutions for the application of iPSC technology in regenerative medicine to treat chronic degenerative diseases. In November 2024, a metabolic disease cooperation project was officially launched with Shanghai Sixth People's Hospital. This is also the first time that iPSC technology has been applied globally to treat such diseases. At present, in the field of Parkinson's treatment, the technical solution developed by the company has successfully completed the in vitro concept verification of the technical solution and the preclinical research effectiveness animal experiments. "Yuan" is the initial, and one yuan gives rise to three. The earth element "Wu" is solid and heavy, and it nourishes all living things. Yuanwu Medicine, taking stem cells as the carrier, starts from the concept of "the right cells, performing the right functions", and uses small molecules to regulate cell fate. While precisely obtaining target phenotypic cells, it also increases the yield of target cells, providing industrialized regenerative medicine solutions for the treatment of chronic degenerative diseases. It will be empowered and applied in the fields of aging, degeneration, and injury in the big health sector. Create disruptive medical value and market value.